SEP 16, 2014 12:00 AM PDT

Interfering with Interferon

WRITTEN BY: Ilene Schneider
Virus-killing molecules may need all their skills, including inflammation, to fight HIV infection. Using the body's natural virus killers to prevent and treat HIV infection has been problematic until now because of the strong inflammatory response these molecules can stimulate as they get rid of the invaders. Now, collaborative research conducted by scientists at the Weizmann Institute and the National Institutes of Health (NIH) have demonstrated how suppressing the activity of these molecules - interferons - around the time of infection could have long-term implications for the course of the disease. Their research appeared in Nature.

Interferons, named for their ability to "interfere" with viral replication, protect us against disease, but they are also the source of inflammation when we are sick. Today, interferons are used to treat such viral diseases as hepatitis. But in HIV, it has been thought that the inflammation and other side effects could be too harmful and the danger of a "runaway" immune response too great. Prof. Gideon Schreiber of Weizmann's Department of Biological Chemistry and his team, including postdoctoral fellow Dr. Doron Levin and former postdoc Dr. Ganit Yarden, had, in previous research, designed an antagonist molecule that is able to block some of the activities of interferons while still allowing them to proceed to act against viruses.

Their original motivation, said Prof. Schreiber, was to better understand the mechanisms of different versions of the interferon molecule. This research revealed that the activity of each interferon is tuned to specific cells and viruses. The molecule they had created, according to Prof. Schreiber, "was not a true ‘antagonist' in the biological sense: Instead of blocking all IFN [interferon] activity, it was able to target the mechanisms leading to the prevention of replication and modulation of the immune system, leaving the antiviral activity mostly intact."

Next, Prof. Schreiber and his group teamed up with Dr. Netanya Sandler and Prof. Daniel Douek at the NIH to understand what happens when full-out interferon activity is tampered with in HIV. The research was done on simian immunodeficiency virus (SIV) - the animal equivalent to HIV. Their results show that the actions blocked by the molecule may have important functions, even if they appear to be "detrimental." The team administered an antagonist, blocking a particular interferon (Type 1 IFN) for the first four weeks after infection. Even after this short period, they found that the natural immune system activities did not recover and compensate to the level they otherwise would have, and this led to a progression of the disease.

Prof. Schreiber explained, "These results clearly demonstrate the importance of an early, general IFN response in fighting HIV infection, and removing the ‘harmful' IFN functions even for just a short period at the onset of infection can have devastating and permanent consequences in shaping the course of disease." Taken together, these findings suggest that not only the type of treatment, but also the timing of IFN administration needs to be considered in the management and prevention of disease. Prof. Gideon Schreiber's research is supported by the Dana and Yossie Hollander Center for Structural Proteomics, which he heads, and the R Baby Foundation.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
AUG 17, 2021
Immunology
Does Fasting Help Protect Against Infection?
AUG 17, 2021
Does Fasting Help Protect Against Infection?
Most people feeling under the weather, especially those with a fever, tend to lose their appetites. When recovering from ...
SEP 06, 2021
Microbiology
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
SEP 06, 2021
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
HIV vaccines have remained elusive in part because the virus has a powerful ability to mutate, and there are so many str ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
SEP 23, 2021
Cardiology
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
SEP 23, 2021
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
Influenza is a severe infectious disease. According to the Centers for Disease Control and Prevention the H1N1 strain of ...
OCT 07, 2021
Immunology
A 3D-Printed COVID Vaccine Patch?
OCT 07, 2021
A 3D-Printed COVID Vaccine Patch?
Even the bravest souls can get a little nervous when it comes to rolling up their sleeves and getting a shot. Aichmophob ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
Loading Comments...